Veterans Getting Closer to Justice at Camp Lejeune
Veterans and their families who were exposed to the contaminated drinking water at Marine Corps Base Camp Lejeune in North Carolina may soon find the justice they have been seeking for many years. The U.S. Senate is expected to soon pass legislation that delivers more comprehensive health care and benefits to veterans affected by all toxic exposure during their service. The Honoring Our PACT Act, a broad, nationwide plan already passed in the House of Representatives, will include the Camp Lejeune Justice Act of 2022, which focuses on four decades of water contamination at the base and the serious health problems it ...
Source: Asbestos and Mesothelioma News - May 19, 2022 Category: Environmental Health Authors: Sophia Clifton Tags: Veterans Source Type: news

Richard Marx health: ‘I thought I was going to die’ - star on lymphoma scare
SINGER Richard Marx, famous for songs like Right Here Waiting, has opened up about his multiple bouts with a "terrifying" mystery illness he thought would end his life. (Source: Daily Express - Health)
Source: Daily Express - Health - May 17, 2022 Category: Consumer Health News Source Type: news

What is in the Differential Diagnosis for Brown and Grey Skin Conditions?
Discussion This is the fourth in a short case series of differential diagnoses of colored skin conditions. An introduction to dermatological terminologies and information about colors can be found here. A differential diagnosis by distribution and common pattern can be found here. For red, orange and yellow conditions, a review can be found here. For green, blue and purple conditions, a review can be found here. For black and white conditions, a review can be found here. Note that any color can be a normal variant for an individual or is physiologic for a given state. Acanthosis nigricans causes dark brown-black patches or...
Source: PediatricEducation.org - May 16, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma
JACKSONVILLE, Fla. — A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell t herapy). The study is published in Cancer Discovery. "CAR-T cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for patients who have relapsed or those who have not responded… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - May 12, 2022 Category: Research Source Type: news

New Mesothelioma Immunotherapy Clinical Trial Opens at MD Anderson
The acclaimed MD Anderson Cancer Center in Houston is opening a phase II clinical trial involving a new immunotherapy drug aimed specifically at advanced, rare cancers, including both pleural and peritoneal mesothelioma. This single-institution clinical trial will be measuring the safety and effectiveness of vudalimab, also known as XmAb20717, which was designed by the California-based biopharmaceutical company Xencor. Vudalimab’s uniqueness stems from its ability to block the activation of cell surface proteins PD-1 and CTLA-4. These proteins stop the immune system from working properly and promote T-cell acti...
Source: Asbestos and Mesothelioma News - May 11, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Source Type: news

' Unprecedented Crisis': Hodgkin Drug Shortage Persists'Unprecedented Crisis': Hodgkin Drug Shortage Persists
In a recent review, researchers went back decades to find the best alternative treatment for patients with advanced classical Hodgkin lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 4, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Response to CAR - T Cell Therapy Similar for Minority Patients
Progression - free and overall survival similar for minority, nonminority patients receiving CAR - T cell therapy for non - Hodgkin lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 3, 2022 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

What is in the Differential Diagnosis for Green, Blue or Violet Skin Conditions?
Discussion Acrocyanosis is commonly seen in the newborn period as the baby transitions to extra-uterine life. It appears as blue-purple coloration of the distal extremities which usually improves over several hours. Blue melanocytosis is also a common normal variant of skin color. It usually is seen on the posterior surface of the body around the spine and buttocks, but can also be on the upper parts of the extremities. It is a blue-black coloration that shows a normal skin undertone when palpated. This is the second in a short case series of differential diagnoses of colored skin conditions. An introduction to dermatologi...
Source: PediatricEducation.org - May 2, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL
(MedPage Today) -- Allogeneic stem-cell transplantation (allo-SCT) after CAR T-cell failure led to durable remissions in patients with relapsed/refractory large B-cell lymphoma (LBCL), according to data from a multicenter series. The results showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 27, 2022 Category: Hematology Source Type: news

EU OK for New Drugs for Lung Cancer and Follicular Lymphoma EU OK for New Drugs for Lung Cancer and Follicular Lymphoma
Capmatinib for lung cancer and mosunetuzumab for follicular lymphoma have been recommended for approval in the European Union.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news

CHMP recommends EU conditional approval of Roche ’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma
If approved, mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat follicular lymphoma (FL) offering a new, off-the-shelf, fixed-duration treatment optionThe recommendation is based on the GO29781 study where mosunetuzumab induced high complete response rates, with the majority of complete responses lasting for at least 18 months in people with heavily pretreated FLBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval under conditional marketin...
Source: Roche Media News - April 22, 2022 Category: Pharmaceuticals Source Type: news

CHMP recommends EU conditional approval of Roche ’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma
If approved, mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat follicular lymphoma (FL) offering a new, off-the-shelf, fixed-duration treatment optionThe recommendation is based on the GO29781 study where mosunetuzumab induced high complete response rates, with the majority of complete responses lasting for at least 18 months in people with heavily pretreated FLBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval under conditional marketin...
Source: Roche Investor Update - April 22, 2022 Category: Pharmaceuticals Source Type: news

What Are the Warning Signs of Lymphoma?
Title: What Are the Warning Signs of Lymphoma?Category: Diseases and ConditionsCreated: 1/7/2022 12:00:00 AMLast Editorial Review: 4/20/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 20, 2022 Category: Cancer & Oncology Source Type: news